| 000 | 01600 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250515102658.0 | ||
| 264 | 0 | _c20080505 | |
| 008 | 200805s 0 0 eng d | ||
| 022 | _a0277-0008 | ||
| 024 | 7 |
_a10.1592/phco.28.1.74 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOfotokun, Ighovwerha | |
| 245 | 0 | 0 |
_aPharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. _h[electronic resource] |
| 260 |
_bPharmacotherapy _cJan 2008 |
||
| 300 |
_a74-81 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aCarbamates _xblood |
| 650 | 0 | 4 |
_aChromatography, High Pressure Liquid _xmethods |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFurans |
| 650 | 0 | 4 |
_aHIV _xdrug effects |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xblood |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndinavir _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganophosphates _xblood |
| 650 | 0 | 4 |
_aProdrugs _xpharmacokinetics |
| 650 | 0 | 4 |
_aRitonavir _xblood |
| 650 | 0 | 4 |
_aSulfonamides _xblood |
| 700 | 1 | _aAcosta, Edward P | |
| 700 | 1 | _aLennox, Jeffrey L | |
| 700 | 1 | _aPan, Yi | |
| 700 | 1 | _aEasley, Kirk A | |
| 773 | 0 |
_tPharmacotherapy _gvol. 28 _gno. 1 _gp. 74-81 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1592/phco.28.1.74 _zAvailable from publisher's website |
| 999 |
_c17666085 _d17666085 |
||